glp 1 white house Patients eligible for GLP-1 weight loss drugs will be able to get at $50 a month: House, #GLP1 #WeightLossDrugs #Medicare #Healthcare #WhiteHouse #USHealthPolicy #ObesityTreatment White House launches discount drug

Levocarnitine-induced hypophosphatemia in a hemodialysis patient with acute valproic acid toxicity

In the results of a cohort study published in BMJ, new users of GLP-1 receptor agonists had a 30% lower risk of severe COPD exacerbation compared to new sulfonylurea users

Curr Med 3 , 14 (2024)

ARC Centre for Cryo-electron Microscopy of Membrane Proteins, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville 3052, VIC, Australia

These medications, originally developed for diabetes management, improve multiple metabolic pathways implicated in metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD)